Recommendations for cervical cancer screening programs in developing countries. The need for equity and technological development

Salud Publica de Mexico

Volumn 45, Issue SUPPL. 3, 2003, Pages

  Lazcano Ponce, Eduardo ^a   Alonso, Patricia ^b   Ruiz Moreno, José Antonio ^c   Hernández Avila, Mauricio ^a  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c Secretaria de la Defensa Nacional   (Mexico)

Author keywords

Cervical cancer; Cervical cytology; Colposcopy; Developing countries; HPV; Screening; Vaccine

Indexed keywords

UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

CANCER SCREENING; COLPOSCOPY; COST; DEVELOPING COUNTRY; DIAGNOSTIC TEST; FEMALE; HEALTH CARE QUALITY; HUMAN; PAPANICOLAOU TEST; POLICY; PRIMARY MEDICAL CARE; QUALITY CONTROL; REVIEW; RURAL AREA; SOCIOECONOMICS; TECHNOLOGY; URBAN AREA; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; WART VIRUS;

EID: 0348050473     PISSN: 00363634     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0036-36342003000900020     Document Type: Review

References (43)

1. Lara E, Day EN, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: Association with organized screening programes. Lancet 1987:1247-1249.
2. Lazcano-Ponce E, Rascón-Pacheco R, Lozano R, Velasco E. Mortality from carcinoma of the uterine cervix in Mexico: impact of screening 1980-1990. Acta Cytol 1996;40:506-512.
3. Miller AB. Cervical cancer screening programes, Geneva: World Health Organization, 1992.
4. Mitchell H. Consistency of reporting endocervical cell. An intralaboratory and interlaboratory assessment. Acta Cytol 1994;38:310-314.
5. Koss LG. Cytology: Accuracy or diagnosis. Cancer 1989;64:249-257.
6. Alonso P, Lazcano E. Quality control in cytopathology laboratories in six Latin American Countries. In: Wied G, Keebler C, Rosenthal D, Schenck U, Somrak T, Vooijs P eds. Compendium on quality assurance, proficiency testing and workload limitations in clinical cytology Chicago: Tutorials of Cytology, 1995:115-121.
7. Lundenberg G. Quality assurance in cervical cytology. The papanicolaou smear. JAMA 1989;262:1672-1679.
8. Muñoz N, Bosch FX, De Sanjose S, Tafur L, Izarzaguza I, Gili M et al. The causal link between human papillomavirus and invasive cervical cancer: A population-based case-control study in Colombia and Spain. Int J Cancer 1992;52:743-749.
9. Zur Hausen H. Papillomaviruses in human cancer. Appl Pathol 1987;5(1):19-24.
10. Walboomers JMM, Jacobs MV, Manos M, Bosch FX, Kummer JA, Shah K et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
11. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Medicine 1997;102:3-8.
12. Galloway D. Is vaccination against human papillomavirus a possibility? Lancet 1998;352:SIII22-SIII24.
13. Pearcy JN, Keppel KG. A Summary measure of health disparity. Public Health Reports 2002;117:273-280.
14. Hinselmann H. Verbesserung der Inspektionmöglichkeiten von Vulva, Vagina und portio. Münch Med Wschr 1925;72:1733.
15. Bjorge T, Thoresen SO, Skare GB. Incidence, survival and mortality in cervical cancer in Norway, 1956-1990. Eur J Cancer 1993;29A(16):2291-2297.
16. Megevand E, Denny L, Dehacek K y cols. Acetic acid visualization of the cervix: An alternative to cytologic screening. Obstet Gynecol 1996;88:383-386.
17. University of Zimbawe/JHPIEGO Cervical Cancer Project. Visual inspection with acetic acid for cervical-cancer screening: test qualities in a primary-care setting. Lancet 1999;353:869-873.
18. Sigurdsson K. Effect of organized screening on the risk of cervical cancer. Evaluation of screening activity in Iceland, 1964-1991. Int J Cancer 1993 Jun 19;54(4):563-70.
19. Herrero R. Epidemiology of cervical cancer. J Natl Cancer Inst Monogr 1996;21:1-6.
20. Editorial. Cell Content of Cervical Smears. Cytopathol 1990;1:129-130.
21. Herbert A. Achievable Standards, Benchmarks for Reporting and Criteria for Evaluating Cervical Cytopathology. Cytopathol 1995;6:1-32.
22. Martin-Hirsch P, Lilford R, Jarvis G, Kitchener HC. Efficacy of cervical-smear collection devices: a systematic review and meta-analysis. The Lancet 1999;354(9192):1763-1770.
23. McCord ML, Stovall TG, Meric JL, Summitt RL Jr, Coleman SA. Cervical cytology: A randomized comparison of four sampling methods. Am J Obstet Gynecol. 1992;166:1772-1779.
24. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338(7):423-438.
25. Sawaya GF, Grimes DA. New technologies in cervical cytology screening: A word of caution. Obstet Gynecol 1999;94:307-310.
26. Iftner T, Villa LL. Chapter 12: Human papillomavirus technologies. J Natl Cancer Inst Monogr. 2003;(31):80-8.
27. Salmerón J, Lazcano-Ponce E, Lörincz A, Hernández M, Hernández P, Leyva A et al. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Cancer Causes and Control 2003;14(6):505-512.
28. Lörincz AT, Richart RM. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med 2003;127(8):959-968.
29. Castle PE, Schiffman M, Gravitt PE, Kendall H, Fishman S, Dong H et al. Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol 2002;68(3):417-423.
30. Garner EI. Cervical cancer: Disparities in screening, treatment, and survival. Cancer Epidemiol Biomarkers Prev 2003;12(3):242S-247S.
31. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ; ASCCP-Sponsored Consensus Conference. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002;287(16):2120-9.
32. Paraskevaldis E, Koliopoulos G, Alamanos Y, Malamou-Mitsi V, Lolis ED, Kitchener HC. Human papillomavirus testing and the outcome of treatment for cervical intraepithelial neoplasia. Obstet Gynecol 2001;98(5 Pt 1):724-725.
33. Richart RM. Current concepts in obstetrics and gynecology. The patient with abnormal Pap smear-screening techniques and management. N Engl J Med 1980;302:332-334.
34. National Cancer Institute Workshop. The 1988 Bethesda System for reporting cervical/vaginal cytologic diagnoses. JAMA 1989;262:931-934.
35. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, and Forum Group Members; Bethesda 2001 Workshop. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287(16):2140-2141.
36. O'Meara AT. Present standards for cervical cancer screening. Curr Opin Oncol 2002;14:505-511.
37. Elfgren K, Kalantari M, Moberger B et al. A population-based five year follow-up study of cervical human papillomavirus infection. Am J Obstet Gynecol 2000;183:561-567.
38. Lörincz AT: Molecular methods for the detection of human papillomavirus infection. Obstet Gynecol Clin NA 1998;23:707-730.
39. Autillo-Touati A, Joannes M, d'Ercole C, Robaglia-Schlupp A, Lambert A, Mazzella E et al. HPV typing by in situ hybridization on cervical cytologic smears with ASCUS. Acta Cytol. 1998 May-Jun;42(3):631-8.
40. Sun Sun CA, Liu JF, Wu DM, Nieh S, Yu CP, Chu TY. Viral load of high-risk human papillomavirus in cervical squamous intraepithetial lesions. Int J Gynaecol Obstet. 2002;76(1):41-47.
41. Steindel SJ, Granade S, Lee J, Avery G, Clarke LM, Jenny RW et al. Practice patterns of testing waived under the clinical laboratory improvement amendments. Arch Pathol Lab Med. 2002;126(12):1471-1479.
42. Saturno PJ, Quintana O, Varo J. ¿Qué es la calidad?. En: Saturno PJ, et al. Tratado de calidad asistencial en atención primaria. Tomo I. Murcia: Du Pont Pharma, 1997:19-45.
43. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB et al. Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med, 2002;347(21):1645-1651.